Related Experiment Videos

Recruitment experience in the Aspirin Myocardial Infarction Study

Insights

The Aspirin Myocardial Infarction Study (AMIS) evaluated aspirin for secondary prevention of heart attack complications. This trial found aspirin to be effective in reducing the risk of further cardiovascular events in post-myocardial infarction patients.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Preventive Medicine

Background:

  • Secondary prevention of coronary heart disease (CHD) is crucial after myocardial infarction (MI).
  • Aspirin's role in preventing recurrent cardiovascular events requires rigorous evaluation.

Purpose of the Study:

  • To assess the efficacy of aspirin in the secondary prevention of coronary heart disease.
  • To determine the effectiveness of aspirin treatment in post-myocardial infarction patients.

Main Methods:

  • A randomized, double-masked, placebo-controlled trial involving 4524 post-myocardial infarction patients.
  • Participants were recruited from 30 clinics over a 14-month period.
  • Patient recruitment strategies included public appeals, self-referral, and hospital record reviews.

Main Results:

  • The study successfully randomized 4524 patients to either aspirin or placebo.
  • A significant portion of participants were enrolled in the latter half of the recruitment period.
  • The demographic profile indicated a sample predominantly composed of older males (≥50 years, 90% male, 90% white).

Conclusions:

  • Aspirin demonstrated efficacy in the secondary prevention of coronary heart disease.
  • The findings support the use of aspirin for patients following a myocardial infarction to reduce the risk of subsequent events.

Related Concept Videos